Relay's TeamTranslate Removes Language Barriers for Frontline Teams and Helps Ease Labor Shortages
Breakthrough AI functionality allows real-time language translation via talk or text for teams using RelayRALEIGH, N.C., May 23, 2024 /PRNewswire/ -- Since launching in 2020, Relay has enabled face-t
Relay Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and
Relay Therapeutics to Host New Program and Platform Event on June 6, 2024
CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and
Relay Therapeutics Upgraded by Barclays Ahead of Data Readout
Express News | Barclays Upgrades Relay Therapeutics to Overweight, Maintains Price Target to $15
Express News | Relay Therapeutics Inc : Barclays Raises to Overweight From Equal Weight
Optimistic Buy Rating for Relay Therapeutics: Pipeline Progress and Financial Stability Drive Analyst Confidence
Relay Therapeutics Price Target Maintained With a $24.00/Share by JMP Securities
Relay Therapeutics Price Target Maintained With a $24.00/Share by JMP Securities
Express News | Relay Therapeutics : Oppenheimer Cuts Target Price to $25 From $33
Express News | Oppenheimer Reiterates Outperform on Relay Therapeutics, Lowers Price Target to $25
Relay Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/06/2024 256.63% Oppenheimer $33 → $25 Reiterates Outperform → Outperform 02/22/2024 327.96% Stifel $25
Analysts Are Bullish on These Healthcare Stocks: Relay Therapeutics (RLAY), Kura Oncology (KURA)
We Think Relay Therapeutics (NASDAQ:RLAY) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew rec
Relay Therapeutics First Quarter 2024 Earnings: Beats Expectations
Express News | Relay Therapeutics Inc : Stifel Cuts Target Price to $28 From $30
Barclays Keeps Their Hold Rating on Relay Therapeutics (RLAY)
Relay Therapeutics GAAP EPS of -$0.62 Beats by $0.10, Revenue of $10.01M Beats by $9.09M
Express News | Relay Therapeutics Inc: About $750 Mln in Cash, Cash Equivalents & Investments at End of Q1, Expected to Fund Operations Into Second Half of 2026
Earnings Flash (RLAY) RELAY THERAPEUTICS Reports Q1 Revenue $10M
04:25 PM EDT, 05/02/2024 (MT Newswires) -- Earnings Flash (RLAY) RELAY THERAPEUTICS Reports Q1 Revenue $10M
Express News | Relay Therapeutics Q1 Net Income USD -81.387 Million